# Pharmacogenetic Dosing of Warfarin

> **NCT02065388** · PHASE3 · COMPLETED · sponsor: **Academia Sinica, Taiwan** · enrollment: 300 (actual)

## Conditions studied

- Stroke
- Venous Thrombosis
- Atrial Fibrillation
- Atrial Flutter

## Interventions

- **BEHAVIORAL:** Standard of care dosing for warfarin
- **GENETIC:** Genotype-guided dosingTaiwan algorithm for warfarin
- **GENETIC:** Genotype-guided dosing IWPC algorithm for warfarin

## Key facts

- **NCT ID:** NCT02065388
- **Lead sponsor:** Academia Sinica, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2014-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065388, "Pharmacogenetic Dosing of Warfarin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02065388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*